Literature DB >> 25161372

Chemical delivery systems and soft drugs: Retrometabolic approaches of drug design.

Yashumati Ratan Bhardwaj1, Ashutosh Pareek1, Vivek Jain1, Dharma Kishore2.   

Abstract

Inclusion of metabolic considerations in the drug design process leads to significant development in the field of chemical drug targeting and the design of safer drugs during past few years which is a part of an approach now designated as Retro metabolic drug design (RMDD). This approach represents systematic methodologies that integrate structure-activity and structure-metabolism relationships and are aimed to design safe, locally active compounds with an improved therapeutic index. It embraces two distinct methods, chemical delivery systems and a soft drug approach. Present review recapitulates an impression of RMDD giving reflections on the chemical delivery system and the soft drug approach and provides a variety of examples to embody its concepts. Successful application of such design principles has already been applied to a number of marketed drugs like esmolol; loteprednol etc., and many other candidates like beta blockers, ACE inhibitors, alkylating agents, antimicrobials etc., are also under investigation.

Entities:  

Keywords:  Absorption; Angiotensin converting enzyme; Chemical delivery system; Distribution; Excretion; Metabolism; Retrometabolic drug design; Soft drug design; Soft drugs

Year:  2013        PMID: 25161372      PMCID: PMC4142369          DOI: 10.1016/j.jsps.2013.04.004

Source DB:  PubMed          Journal:  Saudi Pharm J        ISSN: 1319-0164            Impact factor:   4.330


  39 in total

Review 1.  Soft drug design: general principles and recent applications.

Authors:  N Bodor; P Buchwald
Journal:  Med Res Rev       Date:  2000-01       Impact factor: 12.944

2.  Identification and structure-activity studies of novel ultrashort-acting benzodiazepine receptor agonists.

Authors:  Jeffrey A Stafford; Gregory J Pacofsky; Richard F Cox; Jill R Cowan; George F Dorsey; Stephen S Gonzales; David K Jung; George W Koszalka; Maggie S McIntyre; Jeffrey H Tidwell; Robert P Wiard; Paul L Feldman
Journal:  Bioorg Med Chem Lett       Date:  2002-11-04       Impact factor: 2.823

3.  Soft quaternary anticholinergics: comprehensive quantitative structure-activity relationship (QSAR) with a linearized biexponential (LinBiExp) model.

Authors:  Peter Buchwald; Nicholas Bodor
Journal:  J Med Chem       Date:  2006-02-09       Impact factor: 7.446

4.  Soft drugs. 21. Design and evaluation of soft analogs of propantheline.

Authors:  G Brouillette; M Kawamura; G N Kumar; N Bodor
Journal:  J Pharm Sci       Date:  1996-06       Impact factor: 3.534

Review 5.  Redox drug delivery systems for targeting drugs to the brain.

Authors:  N Bodor
Journal:  Ann N Y Acad Sci       Date:  1987       Impact factor: 5.691

6.  Targeting of drugs to the brain.

Authors:  N Bodor
Journal:  Methods Enzymol       Date:  1985       Impact factor: 1.600

7.  Ester derivatives of 2,6-bis(1-pyrrolidinylmethyl)-4-benzamidophenol as short-acting antiarrhythmic agents. 1.

Authors:  D M Stout; L A Black; C Barcelon-Yang; W L Matier; B S Brown; C Y Quon; H F Stampfli
Journal:  J Med Chem       Date:  1989-08       Impact factor: 7.446

8.  Strategies to target kyotorphin analogues to the brain.

Authors:  P Chen; N Bodor; W M Wu; L Prokai
Journal:  J Med Chem       Date:  1998-09-24       Impact factor: 7.446

9.  Soft drugs. 2. Soft alkylating compounds as potential antitumor agents.

Authors:  N Bodor; J J Kaminski
Journal:  J Med Chem       Date:  1980-05       Impact factor: 7.446

10.  Site- and stereospecific ocular drug delivery by sequential enzymatic bioactivation.

Authors:  N Bodor; L Prokai
Journal:  Pharm Res       Date:  1990-07       Impact factor: 4.200

View more
  4 in total

Review 1.  Structural Modification in Anesthetic Drug Development for Prodrugs and Soft Drugs.

Authors:  Chaoyi Deng; Jin Liu; Wensheng Zhang
Journal:  Front Pharmacol       Date:  2022-07-01       Impact factor: 5.988

2.  A retrospective analysis of the use of loteprednol etabonate ophthalmic suspension 0.5% following canaloplasty.

Authors:  Mahmoud A Khaimi
Journal:  Clin Ophthalmol       Date:  2018-02-12

3.  Eco-friendly methoximation of aromatic aldehydes and ketones using MnCl2.4H2O as an easily accessible and efficient catalyst.

Authors:  Melina C Ontivero; Teodoro S Kaufman; Iván Cortés; Andrea B J Bracca
Journal:  R Soc Open Sci       Date:  2021-07-28       Impact factor: 2.963

4.  Discovery of super soft-drug modulators of sphingosine-1-phosphate receptor 1.

Authors:  Mark Bell; David Foley; Claire Naylor; Colin Robinson; Jennifer Riley; Ola Epemolu; Paul Scullion; Yoko Shishikura; Elad Katz; W H Irwin McLean; Paul Wyatt; Kevin D Read; Andrew Woodland
Journal:  Bioorg Med Chem Lett       Date:  2018-07-30       Impact factor: 2.823

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.